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INTRODUCTION
The routine use of estimated glomerular filtration rate 
to measure kidney function has resulted in improved 
diagnosis of chronic kidney disease (CKD) and a better 
understanding of its epidemiology. In developed coun-
tries, CKD stages 3–5 affects approximately 10% of the 
population [1,2]. CKD, even in its mildest forms, is 
associated with increased morbidity and mortality [3] 
and is therefore now recognized as a major public health 
problem. Not all patients with CKD will progress to 
renal failure and a requirement for renal replacement 
therapy, but an increasing number of patients are reach-
ing this stage [4]. This has major significance for both 
the individual and for health care providers. There is 
thus considerable interest in ways to slow the progres-
sion of CKD, and angiotensin-converting enzyme in-
hibitors and angiotensin receptor blockers are now part 
of routine practice in an attempt to achieve this. How-
ever, progress in this area has been hampered by an 
incomplete understanding of the biological processes 
that lead to progression of CKD.
The histological features of the kidney in CKD—
namely glomerular sclerosis, tubular atrophy and tubu-
lointerstitial (TI) fibrosis—are similar irrespective of 
the initial disease. This suggests that common injurious 
pathways are activated in the damaged kidney that lead 
to a further decline in function. Nephrologists have 
known for many decades that the immune system, in-
cluding activation of the complement system of proteins, 
is responsible for many kidney diseases. The deposition 
of complement proteins in the glomerulus in inflam-
matory glomerulonephritis is well known. However, 
there is increasing evidence that the immune system 
may also be involved in the TI injury that occurs in 
CKD. In this review, we discuss the involvement of 
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the complement system in the development of intersti-
tial renal injury.
PATHOLOGY OF CKD
Many forms of progressive, noncystic CKD originate 
in the glomerulus, but they are almost invariably associ-
ated with histological injury to the tubulointerstitium. 
In fact, it is the severity of TI injury that predicts over-
all renal prognosis, better than the degree of histological 
damage to the glomerulus [5,6]. Therefore, there has 
been increasing interest in the mechanisms underlying 
the development of TI injury [7].
An increase in fibroblast number is a crucial event 
in mediating CKD progression. In healthy kidneys, fi-
broblasts are in a quiescent state and are responsible for 
the maintenance of extracellular matrix homeostasis 
with a balance between matrix synthesis and degrada-
tion. However, during renal injury, activated fibroblasts 
are present in increased numbers and with increased 
capacity to produce matrix. The imbalance between the 
synthesis and degradation of matrix proteins leads to 
irreversible changes in renal structure and function [8]. 
The accumulation of fibroblasts, particularly activated 
myofibroblasts, could be due to proliferation of resident 
fibroblasts or migration of fibroblast precursors from 
the bone marrow [9]. More recently, accumulating data 
suggest that fibroblasts may be derived from tubular 
epithelial cells through the process of epithelial to mes-
enchymal transition [10].
PROTEINURIA AND CKD PROGRESSION
These observations raise one key question: Why does 
glomerular disease result in pathology at a distant site 
within the tubulointerstitium? Several explanations have 
been proposed for this, including:
•  changes in post-glomerular blood flow leading to 
interstitial hypoperfusion and ischemia;
•  downstream effects on the tubulointerstitium of cy-
tokines and growth factors released from the injured 
glomerulus;
•  loss of immune tolerance to kidney antigens due to 
glomerular injury;
•  changes in glomerular permselectivity with leak of 
serum proteins into the urine that damage the tubular 
epithelium.
Proteinuria is common in CKD and occurs by two 
distinct but not exclusive mechanisms. It may be a mani-
festation of the original renal disease or can occur in any 
kidney disease with a significant reduction in the nephron 
number due to hyperfiltration in surviving nephrons.
The weight of clinical and experimental evidence 
has led to the hypothesis that the development of 
proteinuria is a major cause of TI injury [11] rather 
than simply a marker of the severity of glomerular 
disease. The amount of proteinuria is a strong predictor 
of prognosis in renal disease, with high levels of pro-
teinuria predicting an ominous outcome [12]. Interven-
tions that reduce the amount of protein in the urine, 
for example with angiotensin-converting enzyme in-
hibitors or angiotensin receptor blockers, improve the 
renal prognosis in proteinuric nephropathies [13–15]. 
There is also a clear link between proteinuria and 
TI damage and, in animal models, induction of glom-
erular proteinuria leads to TI damage [16]. A number 
of factors present in the urine of proteinuric patients 
have been proposed as mediators of progressive injury 
in CKD. Albumin is a major component of the protein 
that leaks into the urine and direct toxicity of albumin 
is therefore possible. A significant correlation was found 
between glomerular hyalinosis and the level of albu-
minuria in rats with 5/6th reduction in renal mass [17]. 
In vitro studies have shown that exposure of proximal 
tubular epithelial cells (PTECs) to albumin results in 
the production of a variety of chemoattractant, profi-
brotic agents and vasoconstrictive agents that may 
contribute to TI inflammation [18]. It has been suggested 
that the fatty acids carried by albumin may be respon-
sible for the cytotoxicity of albumin to PTECs [19]. 
However, the effect of albumin on PTECs in vitro 
has not been confirmed in vivo. In minimal change 
disease, there is a high level of albuminuria but without 
TI injury and loss of kidney function. Lipoproteins 
[20] and growth factors [21] in the urine have also 
been proposed to be mediators of CKD progression.
In nonselective proteinuria, the urine contains all 
the proteins that are in the serum [22]. Complement 
proteins are a major constituent of serum protein 
(10% of total serum protein) and are found in the 
urine of proteinuric patients. It is conceivable that 
persistent leakage of complement proteins into the 
urine may be injurious to the cells of glomeruli and 
tubules, and this may contribute to the progression 
of CKD.
COMPLEMENT IN PROTEINURIA-ASSOCIATED 
TI INJURY
The complement system is made up of over 30 serum 
and membrane-bound proteins and is an integral 
part of the innate immune system, but also has a key 
role in augmenting adaptive responses. It is activated 
by three pathways: the classical, alternative and 
mannose-binding lectin pathways. These lead to the 
assembly of the pivotal C3 and C5 convertases that 
generate proteins with chemotactic, opsonic, inflamma-
tory and cytolytic activity. In proteinuria, the tubular 
epithelial cells are exposed to complement proteins, 
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the activation of which can alter tubular cell function 
and contribute to chronic TI injury.
Complement is activated in the tubules during 
proteinuria
There is evidence from clinical studies that complement 
is activated within the lumen of tubules in proteinuric 
patients. The membrane attack complex, C5b-9, can 
be detected in the urine of patients with glomerular 
disease at a much higher concentration than in urine 
from healthy individuals [23]. This is true even if the 
primary disease is not associated with glomerular 
complement activation, e.g. diabetic nephropathy. In a 
second study, complement activation products (iC3b, 
Bb, MAC) were almost undetectable in the urine of 
healthy subjects, but there was a significant increase in 
the urinary concentration of these products in proteinu-
ric patients that was proportional to the level of protei-
nuria [24]. This was true of most diseases studied, 
including focal glomerular sclerosis, IgA nephropathy, 
membranous nephropathy and diabetic nephropathy. 
Interestingly, this association was not seen in minimal 
change disease, which is not usually associated with 
TI injury despite high levels of proteinuria.
Immunohistochemical analysis of 46 human kidney 
biopsies with various glomerulopathies found that, ir-
respective of the type of glomerular disease, there is a 
strong correlation between tubular C5b-9 deposition 
and interstitial monocyte infiltration and interstitial 
volume expansion [25]. This observation does not prove 
that C5b-9 has a causal role in the development of injury 
but is certainly supportive of this hypothesis. As the 
C5b-9 complex is about 1,000 kDa, it is unlikely to be 
filtered into the urine, again suggesting that complement 
is activated in the tubular compartment.
Activation of complement by PTECs
PTECs have the capacity to activate the complement 
system. When acetone-fixed rat or human kidney 
sections were incubated with fresh normal human 
serum (NHS), fixation of C3 occurred along the luminal 
border of proximal tubules. This fixation was not 
found on other tubular segments or in glomeruli. In 
addition to C3, properdin deposition occurred (but 
not C1q, C4, IgG, IgA or IgM) [26]. The addition to 
fresh serum of Mg-EGTA, which blocks the classical 
but not the alternative pathway, did not influence the 
binding of complement to the tubules [27]. Both 
observations suggest that complement is activated 
through the alternative pathway on the brush border of 
proximal tubules. Incubation of cultured, heat-killed, 
human kidney cells with NHS activates complement. 
This complement activation is largely dependent on 
factor B [28]. Human PTECs incubated with NHS fixed 
C3, properdin and C5b-9 on their surface, but not 
C1q or C4. Complement fixation was abrogated if 
PTECs were incubated with EDTA-treated NHS or C3-
deficient human serum, but not with Mg-EGTA-treated 
NHS or C1q-deficient human serum, again confirming 
the important role of the alternative pathway [29].
The mechanism of complement activation
Protein overload in tubular cells is associated with 
ammonium production. It has been shown that C3 
treated with ammonium hydroxide has properties 
comparable to those of soluble C3b. C3 modified by 
ammonia is called amidated C3, and can form the 
alternative pathway convertase of the complement 
cascade [30] and may contribute to TI injury [31]. 
Acidification of the urine within the tubular lumen 
may also enhance complement activation [32]. Nucle-
ated cells express complement regulatory proteins 
to protect themselves against inappropriate comple-
ment activation. However, Ichida et al reported 
that there was a paucity of complement regulators 
on the apical surface of tubular cells [33]. Decay 
accelerating factor was not expressed in proximal 
tubules and membrane cofactor protein was only 
expressed on basolateral membranes. CD59 was 
weakly expressed in the brush border of proximal 
tubules [33]. This deficiency of complement reg-
ulatory proteins on the luminal side of proximal 
tubules may allow uncontrolled activation of 
complement.
COMPLEMENT ACTIVATION INFLUENCES 
TI INJURY
Animal models have been used to demonstrate the causal 
link between complement activation and TI injury. 
Several approaches have been employed.
The use of complement-deficient animals
C6-deficient rats have been used to study the effects of 
C5b-9 in disease development. Equivalent levels of 
proteinuria were induced in wild type or C6-deficient 
rats by puromycin. However, wild type rats developed 
more severe histological TI injury than C6-deficient 
rats, suggesting that C5b-9 formation during proteinuria 
contributes to TI damage [34]. This may be due to C5b-9 
causing accumulation of interstitial myofibroblasts 
[35], although the mechanism by which this occurs is 
unknown. Similarly, in rats with proteinuria induced 
by 5/6 nephrectomy, C6 deficiency was protective, re-
ducing TI damage and functional loss [36]. In contrast 
to these results, the C6-deficient rats were not protected 
from other non-proteinuric renal injury [37].
Turnberg et al found that mice deficient in C3 were 
protected from TI injury following induction of pro-
teinuria by adriamycin [38]. Factor D-deficient mice 
were also protected and no C3 deposition was seen on 
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tubular cells in adriamycin-induced proteinuria in the 
absence of factor B [39]. The absence of complement 
regulator CD59 exacerbated disease [39]. This is 
consistent with the study in the C6-deficient rats sug-
gesting a pathogenic role for C5b-9 [34], and with 
the human biopsy study that demonstrated CD59 on 
the luminal surface of tubular epithelial cells [33]. The 
adriamycin nephropathy model has also been used to 
study the role of locally synthesized C3. Using a trans-
plantation strategy, mice with absent renal synthesis 
of C3 developed milder TI injury than mice with the 
capacity to synthesize C3 in their kidneys [40]. This 
suggests a role for local C3 synthesis in the development 
of TI inflammation and fibrosis. However, in contrast, 
the results of a protein overload model suggest a pre-
dominant role for ultrafiltered C3 [41].
The use of complement depletion or 
inhibition to prevent injury
Depletion of complement with cobra venom factor and 
the use of biological inhibitors have both been used 
to study the role of complement in the development 
of TI injury. Cobra venom factor treatment reduced 
proteinuria-associated TI injury in puromycin-induced 
nephropathy [42] and anti-Thy-1 nephritis [43]. Soluble 
complement receptor 1, a complement inhibitor based 
on the human receptor, had a similar effect on TI injury 
in these two models [42,43]. A more recent study 
coupled a single-chain antibody fragment directed 
against a tubular antigen to Crry (complement receptor-
related protein, the rodent analog to decay accelerating 
factor and membrane cofactor protein), thereby target-
ing the inhibitor to tubules. This inhibitor-targeting 
approach reduced injury and preserved renal function 
after the induction of puromycin nephropathy [44].
As an alternative to inhibiting complement, Hori 
et al used antisense oligodeoxynucleotides against 
Crry to reduce expression and thereby increase sus-
ceptibility to complement-mediated injury. When in-
jected into a rat, anti-Crry oligodeoxynucleotides 
reduced expression of Crry protein by PTECs. After the 
induction of proteinuria, more severe TI injury was 
found in anti-Crry oligodeoxynucleotide-treated 
animals compared with controls [45].
Complement inhibitors are important in 
maintaining tissue integrity
The studies discussed above demonstrate that comple-
ment activation causes TI injury in proteinuric disease. 
However, there is also evidence that spontaneous 
complement activation can cause TI injury in an other-
wise normal kidney. If a rat kidney is perfused with 
monoclonal antibodies that block the activity of the 
complement inhibitors Crry and CD59, tubular injury 
occurs [46]. Damage occurs if Crry alone is inhibited 
but is worsened if CD59 is also inhibited, implicating 
a role for C5b-9 [47]. This is prevented by the depletion 
of C3. Crry knockout is embryolethal, but mice can 
be salvaged by generating double knockouts of Crry 
and C3. If a kidney from a Crry/C3 knockout is trans-
planted into a mouse with an intact systemic comple-
ment system, spontaneous complement activation 
occurs within the kidney with tubular injury and inter-
stitial fibrosis, leading to renal failure and death from 
renal failure within 3 weeks [48].
The role of anaphylatoxins in TI injury
The release of anaphylatoxins as a consequence of 
complement activation can also cause renal injury. 
Bao et al found that either C3a receptor antagonist 
or C5a receptor antagonist blocked TI injury in 
experimental lupus nephritis in mice [49,50]. How-
ever, it is not possible to distinguish between a 
direct effect of anaphylatoxins on the kidney and the 
development of autoimmunity. Although no role for 
C5b-9 was demonstrated in non-proteinuric renal 
disease, Boor et al demonstrated an important role 
for C5a in the development of TI injury [51]. C5 
deficiency and C5a receptor antagonist treatment 
reduced the degree of TI fibrosis in mice that had 
undergone unilateral ureteral obstruction [51]. Our 
recent results also suggest that anaphylatoxins 
contribute to injury in proteinuric nephropathy 
[52,53]. A similar key role for C5a in the development 
of proteinuria-associated TI injury in the horse 
apoferritin model has also been reported [54].
How does complement cause TI injury?
Complement activation on tubular epithelial cells can 
induce the production of a range of proinflammatory 
and profibrotic mediators. C5b-9, C3a and C5a have all 
been shown to increase the production of chemokines 
[55], cytokines [56], growth factors [57] and matrix 
proteins [58–60], and also to increase the immunogenic 
potential of PTECs [61]. In addition, our experiments 
have shown that C3a can stimulate cultured PTECs in 
vitro to undergo epithelial to mesenchymal transition, 
including loss of E-cadherin, acquisition of α-smooth 
muscle actin, and production of collagen I [52,53]. 
Alternatively, the chemotactic effects of anaphylatoxins 
and the extensively reported ability of these proteins to 
activate cells of myeloid origin may be important [62]. 
At present, we do not know which effect of complement 
contributes most to the development of injury, and it 
may be that many, and perhaps all, of these functions 
are important.
CONCLUDING REMARKS
Proteinuria is associated with TI injury and both predict 
a poor renal prognosis. Evidence of complement 
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activation can be found in proteinuric urine and this 
may contribute to the progression of TI fibrosis. Inhibi-
tion of complement activation or the actions of anaphy-
latoxins can block the progression of CKD. At present, 
however, most of the evidence to support this is based 
on studies in experimental animals. The next and most 
challenging step is to translate these experimental 
observations into treatments that influence patient 
outcome.
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